These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2275292)

  • 1. [Recommendations of the study group "Hormone substitution in postmenopause after breast cancer" of the German Society for Breast Diseases].
    Maass H; Brändle LW; von Fournier D; Lauritzen C; Schulz KD
    Zentralbl Gynakol; 1990; 112(18):1169-70. PubMed ID: 2275292
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estrogens in menopause--therapy and prevention. I. Hormone substitution in climacteric and postmenopause].
    Wuttke W
    Internist (Berl); 1996 Apr; 37(4):402-5. PubMed ID: 8655280
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hormone substitution in climacteric. Position of the German Menopause Society].
    Schneider HP; Kuhl H; Dören M; Hesch D
    Zentralbl Gynakol; 1995; 117(6):B1-4. PubMed ID: 7645352
    [No Abstract]   [Full Text] [Related]  

  • 5. Polish consensus: procedure in case of estrogen deficiency in women after breast cancer therapy.
    Milewicz A; Szymański W; Ruzyłło W; Zgliczyński S; Reinfus M; Zieliński J; Debski R; Demissie M; Tworowska U
    Gynecol Endocrinol; 2002 Oct; 16(5):385-9. PubMed ID: 12587533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of estrogen and gestagen substitution in peri and postmenopause].
    Birkhäuser M
    Praxis (Bern 1994); 1997 Jan; 86(5):125-8. PubMed ID: 9064729
    [No Abstract]   [Full Text] [Related]  

  • 7. [Menopausal symptoms in breast carcinoma patients. Is effective treatment possible?].
    Rauthe G
    Fortschr Med; 1996 Feb; 114(5):46-8. PubMed ID: 8867475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recommendations for substitution with estrogens and progesterones in climacteric and in postmenopause. 8th Professional Meeting of the Zurich Discussion Group, November 1992].
    Bettendorf G; Breckwoldt M; Keller PJ; Kuhl H; Runnebaum B; Teichmann AT
    Gynakol Geburtshilfliche Rundsch; 1993; 33(1):39-40. PubMed ID: 8471884
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone replacement therapy and breast cancer risk.
    Gambrell RD
    Arch Fam Med; 1996 Jun; 5(6):341-8. PubMed ID: 8640324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term hormone replacement and risk of breast carcinoma: current status. On behalf of the German Menopause Society and the Professional Society of Gynecologic Endocrinology and Reproductive Medicine of the German Society of Gynecology and Obstetrics].
    Kuhl H; Runnebaum B; Schneider HP
    Zentralbl Gynakol; 1995; 117(10):549-53. PubMed ID: 7491838
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zurich Discussion Circle, October 2003].
    Birkhäuser M; Braendle W; Keller PJ; Kiesel L; Kuhl H; Neulen J
    Gynakol Geburtshilfliche Rundsch; 2004 Oct; 44(4):258-64. PubMed ID: 15459525
    [No Abstract]   [Full Text] [Related]  

  • 13. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C; Reeves G
    Lakartidningen; 2005 Apr 18-24; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].
    Magnusson C; Weiderpass E
    Lakartidningen; 2001 Jan; 98(5):418-21. PubMed ID: 11229082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone-dependent oncological diseases in menopausal women].
    Tomov S; Baichev G; Gorchev G
    Akush Ginekol (Sofiia); 2000; 39(3):41-5. PubMed ID: 11187996
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmenopausal estrogen replacement therapy in the patient with breast carcinoma.
    Cyr MG
    R I Med; 1995 Sep; 78(9):261-3. PubMed ID: 7579723
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal substitution in climacteric symptoms after cancer treatment].
    Bergkvist L; Frankendal B; Samsioe G; Silfverstolpe G
    Lakartidningen; 1989 May; 86(19):1798-9, 1801-2, 1804. PubMed ID: 2733484
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hormone substitution in climacteric. Position of the German Menopause Society].
    Schneider HP; Kuhl H; Dören M; Hesch D
    Zentralbl Gynakol; 1995; 117(5):229-32. PubMed ID: 7793163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.